Enzon Pharmaceuticals Inc (NASDAQ:ENZN)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.

Results 1 - 16 of 16

Recs

0
Member Avatar BYUofU (50.26) Submitted: 9/14/2013 11:24:46 PM : Outperform Start Price: $1.27 ENZN Score: -29.78

Pipeline, and possible takeover..

Recs

2
Member Avatar jschinagle (< 20) Submitted: 5/13/2013 4:26:19 PM : Underperform Start Price: $1.17 ENZN Score: +27.87

nothing left after large liquidating dividend

Recs

0
Member Avatar Hotpicks101 (28.83) Submitted: 1/21/2011 6:11:35 PM : Outperform Start Price: $3.14 ENZN Score: -119.31

Klarman. Cheap.

Recs

0
Member Avatar jsgant13 (99.14) Submitted: 9/13/2010 1:01:00 PM : Outperform Start Price: $2.97 ENZN Score: -139.23

baupost, deej and value

Recs

0
Member Avatar NoIcons (< 20) Submitted: 2/28/2010 6:33:42 PM : Outperform Start Price: $2.55 ENZN Score: -134.91

outperform

Recs

1
Member Avatar TMFBreakerJava (99.51) Submitted: 11/19/2009 12:34:32 AM : Outperform Start Price: $2.93 ENZN Score: -141.60

This biotech has a reliable royalty revenue stream from its proprietary pegylation technology which makes drugs less toxic, and more effective. It has a solid balance sheet and some interesting compounds in the pipeline. It has just sold off a portfolio of drugs to fix the balance sheet. Undervalued due to years of questionable decisions by management, the new CEO has now put the house in order, which promises appreciation to fair value and more gains if one of the drugs in the pipeline pans out.

Recs

0
Member Avatar healthcare1 (< 20) Submitted: 1/17/2009 5:04:27 AM : Outperform Start Price: $1.69 ENZN Score: -174.26

it has a unique drug delivery system and activist shareholders

Recs

0
Member Avatar mjan706 (67.17) Submitted: 9/22/2008 1:44:10 AM : Outperform Start Price: $2.14 ENZN Score: -111.80

An Icahn portfolio stock.

Recs

0
Member Avatar hennessy7 (54.34) Submitted: 5/26/2008 9:12:50 AM : Outperform Start Price: $2.40 ENZN Score: -103.31

I like the sector. This is a sector pick as I have done little DD on this stock. I think small biotech has been hit hard, and the cancer market, in particular, is going to turn around. Plus, I do not see too many incredible investments in other sectors so I am sticking to high risk/ high reward opportunities.

Recs

0
Member Avatar WonderWolf (51.86) Submitted: 5/20/2008 11:48:35 PM : Outperform Start Price: $2.41 ENZN Score: -99.26

Working on 2 cancer drugs and will be the big winner!!

Recs

0
Member Avatar Addgirl48 (63.54) Submitted: 3/29/2008 11:21:19 AM : Outperform Start Price: $2.52 ENZN Score: -112.79

People all ways needing pills so Pharmaceuticals all ways geting business and all ways will

Recs

0
Member Avatar djinsanity (< 20) Submitted: 2/9/2008 12:17:36 PM : Outperform Start Price: $2.21 ENZN Score: -105.37

PEG-SN38 showed anti-tumor activity in resistant pre-clinical models, FDA approval for DepoCyt, leader in stem cell research, I can see it doing phenomenal

Recs

0
Member Avatar henncoop (91.10) Submitted: 3/7/2007 11:04:59 AM : Outperform Start Price: $2.24 ENZN Score: -101.52

low PE &amp; a good choice for a play in this sector

Recs

0
Member Avatar pbqstraining (< 20) Submitted: 1/12/2007 10:52:34 PM : Outperform Start Price: $2.32 ENZN Score: -99.67

NICE PIPELINE

Recs

0
Member Avatar j3nzsrfs (< 20) Submitted: 11/25/2006 10:29:17 PM : Outperform Start Price: $2.27 ENZN Score: -101.49

New cancer treatment

Recs

0
Member Avatar MadisonClub1 (< 20) Submitted: 11/22/2006 8:11:36 PM : Outperform Start Price: $2.27 ENZN Score: -101.45

All looks bad for it but ....just a feeling

Results 1 - 16 of 16

Featured Broker Partners


Advertisement